Physician profile
Robert Freundlich
NPI 1881692093
$911.55
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $158 · 2021: $263 · 2022: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186.36 | 2020-2022 | |
| Amgen INC. | $158.38 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $140.26 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $92.11 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $52.41 | 2019 | |
| Biogen, INC. | $51.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $43.45 | 2020 | |
| Adamas Pharmaceuticals, INC. | $33.90 | 2019-2021 | |
| Abbott Laboratories | $30.82 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.06 | 2022 | |
| Vertical Pharmaceuticals, LLC | $21.18 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.96 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $19.80 | 2021 | |
| Lilly USA, LLC | $19.15 | 2019 | |
| Acadia Pharmaceuticals INC | $12.96 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Freundlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.